Literature DB >> 15077906

Somatostatin receptor subtypes: basic pharmacology and tissue distribution.

V D Corleto1, S Nasoni, F Panzuto, S Cassetta, G Delle Fave.   

Abstract

The heptahelical receptor superfamily constitutes the largest single family of transmembrane-signalling molecules that regulate a wide range of physiological processes. The five somatostatin receptors represent a distinct subgroup of this seven transmembrane receptor superfamily. They range in size from 356 to 391 amino acids with 39-57% protein identity between the subtypes with 100 residues strictly conserved among the somatostatin receptor sequences. A high grade of mRNA homology exists in somatostatin receptor subtypes cloned from different species. Following somatostatin receptor binding and functional activity studies, two alternative models of ligand-binding interaction have been hypothesised. One relies on the presence of a binding pocket within the receptor structure constituted by specific amino acids residues, the other denies the presence of such binding structures and suggests that it is the interaction of agonists with specific extracellular and/or transmembrane domains that determine stable receptor structure conformation. Somatostatin receptors, as, indeed, all G-protein-coupled receptors are able to regulate their responsiveness to agonist exposure. This agonist-specific regulation includes three main events, namely, desensitisation, receptor internalisation and receptor degradation. The cell expression of somatostatin receptor subtypes, at the mRNA level, has been characterised in rodent and in human organs with multiple subtype expression in brain and peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077906     DOI: 10.1016/j.dld.2003.11.008

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

Authors:  L Bodei; M Kidd; I M Modlin; V Prasad; S Severi; V Ambrosini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli; I Drozdov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236

Review 2.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

Review 3.  Somatostatin as an Active Substance in the Mammalian Enteric Nervous System.

Authors:  Slawomir Gonkowski; Liliana Rytel
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

4.  Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo.

Authors:  Tao Liu; Tingting Jia; Xia Yuan; Cheng Liu; Jian Sun; Zhenhua Ni; Jian Xu; Xuhui Wang; Yi Yuan
Journal:  Int J Nanomedicine       Date:  2016-05-23

5.  Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.

Authors:  Xi Chen; Xiao-Yu Zhang; Yang Shen; Li-Li Fan; Mu-Lan Ren; Yong-Ping Wu
Journal:  Oncotarget       Date:  2016-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.